Association between hepatitis B virus (HBV) reactivation and recurrence of hepatocellular carcinoma (HCC) following direct-acting antiviral (DAA) treatment for hepatitis C.

Association between hepatitis B virus (HBV) reactivation and recurrence of hepatocellular carcinoma (HCC) following direct-acting antiviral (DAA) treatment for hepatitis C. - Association between hepatitis B virus (HBV) reactivation and recurrence of hepatocellular carcinoma (HCC) following direct-acting antiviral (DAA) treatment for hepatitis C.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031368

Enrollment

100

Registered

2018-03-01

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HBs/HBc antibodies and HBV DNA before and after DAA was measured in our patients who achieved SVR24.

Exclusion criteria

Exclusion criteria: none.

Design outcomes

Primary

Measure	Time frame
HBs/HBc antibodies and HBV DNA before and after DAA.	—

Countries

Japan

Contacts

Public ContactToshie Mashiba

Matsuyama Red Cross Hospital Center for Liver-Biliary-Pancreatic Diseases

matoshi@matsuyama.jrc.or.jp089-924-1111

Outcome results